Jefferies Assumes Neurocrine Biosciences at Buy, Announces Price Target of $112
Jefferies analyst Akash Tewari assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $112.
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio’s PRV; RMAT Designation For PolarityTE’s Product
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $126
JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $125 to $126.
Neurocrine Biosciences Reports Regulatory Approval Of Dysval For Treatment Of Tardive Dyskinesia In Japan
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the
Where Neurocrine Biosciences Stands With Analysts
Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter:
Goldman Sachs Upgrades Neurocrine Biosciences to Buy, Announces $115 Price Target
Goldman Sachs analyst Chris Shibutani upgrades Neurocrine Biosciences (NASDAQ:NBIX) from Neutral to Buy and announces $115 price target.
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $100
Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $95 to $100.
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly’s Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Neurocrine Biosciences Q4 EPS $0.04 Down From $0.91 YoY, Sales $312.00M Miss $316.79M Estimate
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $0.04 per share. This is a 95.6 percent decrease over earnings of $0.91 per share from the same period last year. The company reported quarterly sales